KLHL33 Inhibitors
KLHL33 inhibitors comprise a diverse group of chemical compounds that interfere with the protein's normal degradation process within the ubiquitin-proteasome system, leading to its functional inhibition through accumulation. These inhibitors target various components of the proteasome, a multi-catalytic proteinase complex responsible for the degradation of ubiquitinated proteins. By binding to the proteasome's catalytic sites, these inhibitors disrupt the proteolytic activity that would typically serve to regulate the levels of KLHL33 within the cell. The resulting accumulation of KLHL33, along with other proteins, can lead to a state of proteotoxic stress, which in turn can diminish the functional capacity of KLHL33 through indirect mechanisms.
The action of these inhibitors ranges from reversible to irreversible interactions with the proteasome, with some forming a covalent bond leading to sustained inhibition. These small molecules vary in their specificity and potency, yet they all converge on the pathway that controls the turnover of KLHL33. The inhibition of proteasomal activity by these compounds can lead to a dysregulated protein homeostasis or proteostasis, which is characterized by the buildup of not only KLHL33 but also its substrates and interacting partners.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
This proteasome inhibitor binds irreversibly to the 20S proteasome, suppressing the degradation of proteins, including KLHL33, leading to its accumulation and subsequent functional inhibition. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a reversible proteasome inhibitor that prevents the breakdown of ubiquitinated proteins, thereby potentially increasing the levels of KLHL33 and indirectly inhibiting its function due to abnormal accumulation. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin specifically targets the proteasome's catalytic β-subunits, leading to the accumulation of polyubiquitinated proteins and potentially dysregulating KLHL33's normal degradation and function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a dipeptide boronic acid analog that inhibits the 26S proteasome, potentially disrupting the degradation of KLHL33, leading to its inhibition through abnormal protein accumulation. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $40.00 | ||
Carfilzomib irreversibly binds to and inhibits the 20S proteasome's chymotrypsin-like activity, potentially leading to the accumulation of ubiquitinated KLHL33 and its functional inhibition. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib selectively and reversibly inhibits the 20S proteasome, leading to the accumulation of KLHL33 and its potential indirect inhibition through dysregulated proteostasis. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is a proteasome inhibitor that could lead to the accumulation and potential inhibition of KLHL33 by preventing its proteasomal degradation. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib is a proteasome inhibitor that can lead to the accumulation of ubiquitinated proteins including KLHL33, potentially leading to its functional inhibition. | ||||||